Company Announcements

Agreement with Cooper Consumer Health - Correction

Source: RNS
RNS Number : 4344M
Futura Medical PLC
23 May 2022




23 May 2022


 Futura Medical plc

("Futura" or the "Company")


RNS Correction - Futura Announces Collaboration with Cooper Consumer Health to Commercialise MED3000 in EEA, United Kingdom and Switzerland


Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, notes incorrect information in the 'About Cooper Consumer Health boilerplate' in part of its RNS announcement no: 3503M dated 23 May and restates the relevant part of the RNS as follows:

About Cooper Consumer Health
Cooper Consumer Health is the European consolidation platform in the self-medication (OTC) and selfcare field set up by the investment fund Charterhouse Capital Partners in January 2016. Its mission is to develop and market more Selfcare solutions, to more people. It believes responsible Selfcare can contribute to lowering the pressure on national Healthcare systems and reduce system costs. Today, this platform has a leading position in France, the Netherlands, Belgium, Italy, Spain, Portugal and Hong Kong. The 'Cooperation Pharmaceutique Francaise' started just outside Paris more than 100 years ago as a cooperative between pharmacists. It acquired Vemedia Consumer Health in 2016 and Laboratoires Diepharmex in 2019. Meanwhile, the Group has made several brand acquisitions across Europe, including Hexomédine, Essaven, and Dacryoserum. The Group's main brands include Oenobiol, Valdispert, Mag2, Pouxit, Insect Ecran, Audispray and Excilor


For further information please contact:


Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO


Tel: +44 (0) 1483 685 670

Nominated Adviser and Sole Broker:


Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings

Tel: +44 (0) 20 3100 2000


For media enquiries please contact:


Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt


Tel: +44 (0) 203 882 9621


About Futura Medical plc

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialisation strategies are designed to maximise product differentiation and value creation whilst minimising risk.

MED3000 is Futura's topical gel formulation that is a breakthrough treatment for erectile dysfunction ("ED") through a unique evaporative mode of action. Futura has conducted a Phase 3 study using MED3000 in ED, referred to as "FM57". This was a 1,000 patient, dose-ranging, multi-centre, randomised, double blind, placebo-controlled, home use, parallel group study delivering highly statistically significant results compared to pre-treatment baseline, consistently meeting all co-primary endpoints of IIEF, SEP2 and SEP3 (internationally accepted clinical trial endpoints in ED) with over 60% of patients experiencing a clinically meaningful improvement in their ED.  MED3000 also begins to work immediately in some patients, with 60% of patients seeing onset of their erection within 10 minutes of application. MED3000 is CE marked in Europe and the UK as a clinically proven topical treatment for adult men with erectile dysfunction.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.